Roivant Sciences Ltd.
USD35.60
+0.88 (+2.52%)
CEO
Matthew Gline
IPO Date
2020-12-08
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
GB
Open
$34.91
Prev. Close
$34.73
Day Low
$34.77
Day High
$35.90
52W Low
$10.71
52W High
$35.90
Market Cap
$25.61B
Volume
2.08M
| -42.6 |
| 31 Mar 2024 | FY | 95.1% | 13294.2% | 72.9% | 60.2% | 0.08 | 25.24 | 1.9 |
| 31 Mar 2023 | FY | 90.4% | -3200.2% | -87.2% | -42.2% | 0.42 | 6.60 | -5.2 |
| 31 Mar 2022 | FY | 83.8% | -1528.9% | -51.0% | -32.7% | 0.17 | 11.64 | -3.9 |
| 31 Mar 2021 | FY | 91.4% | -3400.9% | -42.6% | -30.1% | 0.13 | 9.99 | -8.3 |
| 31 Mar 2020 | FY | 98.3% | 1773.6% | 59.1% | 48.5% | 0.09 | 24.09 | 5.9 |
| -14.2 |
| 30 Sept 2025 | Q2 | 92.9% | -7225.9% | -2.6% | -2.2% | 0.02 | 33.70 | -22.7 |
| 30 Jun 2025 | Q1 | 92.9% | -10292.9% | -5.1% | -4.4% | 0.02 | 40.54 | -8.6 |
| 31 Mar 2025 | Q4 | 97.3% | -2727.5% | -4.4% | -3.8% | 0.02 | 33.47 | -8.6 |
| 31 Dec 2024 | Q3 | 97.1% | 1878.3% | 3.3% | 2.9% | 0.02 | 37.91 | 12.6 |
| 17 Sept 2024 | Q2 | 94.8% | -5143.8% | -4.5% | -3.7% | 0.01 | 10.43 | -9.6 |
| 30 Jun 2024 | Q1 | 97.3% | 1192.7% | 1.8% | 1.5% | 0.07 | 27.91 | 20.9 |
| 31 Mar 2024 | Q4 | 84.7% | -522.3% | -2.5% | -2.1% | 0.08 | 25.24 | -13.9 |
| 31 Dec 2023 | Q3 | 98.7% | 32747.6% | 83.7% | 69.7% | 0.08 | 27.79 | 0.4 |